Tivity Health Acquires Nutrisystem for $1.3 Billion

We represented Tivity Health, Inc. (Nasdaq: TVTY) in its acquisition of Nutrisystem, Inc. (Nasdaq: NTRI), a provider of weight management products and services, for $1.3 billion. With this acquisition, Tivity Health will be unique in offering, at scale, an integrated portfolio of fitness, nutrition and social engagement solutions to support overall health and wellness. Tivity will maintain all of Nutrisystem’s existing brands, as well as the company’s Fort Washington, Pennsylvania, headquarters. Nutrisystem CEO Dawn Zier will become president and COO of Tivity Health, while Donato Tramuto will remain Tivity’s CEO.

Tivity Health®, Inc. is a leading provider of health improvement, nutrition, fitness, and social engagement solutions at scale to improve clinical outcomes, reduce healthcare costs and create opportunities to feel better, work better and live better.

You Also May Be Interested In:

  • We represented ALS Education, Inc., an education dropout prevention and recovery program, in the sale of its charter school management...
    Client Type: Private Company
  • Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers

    We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company